| 1 |
35203446 | What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review (Part 6): Correlation of PD-L1 Expression with the Status of Mismatch Repair System, BRCA, PTEN, and Other Genes. | 2022 Jan 22 |
1 |
| 2 |
32092597 | Association of BRCA Mutations and BRCAness Status With Anticancer Drug Sensitivities in Triple-Negative Breast Cancer Cell Lines | 2020 Jun |
3 |
| 3 |
31213465 | Chromosome 12p Amplification in Triple-Negative/BRCA1-Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity. | 2019 Aug 15 |
4 |
| 4 |
29189915 | Targeting BRCA1/2 deficient ovarian cancer with CNDAC-based drug combinations. | 2018 Feb |
1 |
| 5 |
27130464 | Expression of BRCA1, a factor closely associated with relapse-free survival, in patients who underwent neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil for squamous cell carcinoma of the esophagus. | 2017 Jan |
1 |
| 6 |
28676659 | Mutations in BRCA2 and taxane resistance in prostate cancer. | 2017 Jul 4 |
1 |
| 7 |
29163710 | Combination of histoculture drug response assay and qPCR as an effective method to screen biomarkers for personalized chemotherapy in esophageal cancer. | 2017 Dec |
2 |
| 8 |
27313763 | Successful personalized chemotherapy for metastatic gastric cancer based on quantitative BRCA1 mRNA expression level: A case report. | 2016 Jun |
3 |
| 9 |
27693788 | Enforced expression of hsa-miR-125a-3p in breast cancer cells potentiates docetaxel sensitivity via modulation of BRCA1 signaling. | 2016 Oct 28 |
1 |
| 10 |
25496700 | Plasma mRNA expression levels of BRCA1 and TS as potential predictive biomarkers for chemotherapy in gastric cancer. | 2014 Dec 14 |
5 |
| 11 |
23326344 | BRCA1 mRNA expression as a predictive and prognostic marker in advanced esophageal squamous cell carcinoma treated with cisplatin- or docetaxel-based chemotherapy/chemoradiotherapy. | 2013 |
3 |
| 12 |
21756279 | Germline BRCA mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancer. | 2012 Mar |
1 |
| 13 |
22807977 | BRCA1 protein levels and PIK3CA mutations as predictive biomarkers for response to neoadjuvant chemotherapy in locally advanced breast cancer: An exploratory analysis. | 2012 Jul |
1 |
| 14 |
23359225 | Individualized Chemotherapy in Advanced NSCLC Patients Based on mRNA Levels of BRCA1 and RRM1. | 2012 Sep |
1 |
| 15 |
21157449 | Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced/metastatic non-small-cell lung cancer. | 2011 Jan 18 |
2 |
| 16 |
21862729 | mRNA expression of BRCA1, PIAS1, and PIAS4 and survival after second-line docetaxel in advanced gastric cancer. | 2011 Oct 19 |
1 |
| 17 |
19249193 | Platinum sensitivity in a BRCA1 mutation carrier with advanced breast cancer. | 2009 Aug |
1 |
| 18 |
19415121 | Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression. | 2009 |
1 |
| 19 |
17492376 | Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers. | 2008 Mar |
1 |
| 20 |
18281755 | [Prediction of response to docetaxel in breast cancer]. | 2008 Feb |
1 |
| 21 |
18402708 | ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel. | 2008 Apr 11 |
4 |
| 22 |
18591931 | Primary resistance to docetaxel-based chemotherapy in metastatic breast cancer patients correlates with a high frequency of BRCA1 mutations. | 2008 Jul |
3 |
| 23 |
19002265 | Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients. | 2008 |
1 |
| 24 |
16805818 | Predictive factors for response to docetaxel in human breast cancers. | 2006 Sep |
1 |
| 25 |
11400119 | Decreased expression of BRCA2 mRNA predicts favorable response to docetaxel in breast cancer. | 2001 Jul 20 |
2 |